Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Med LifeLTS:0RO5 70 EV-to-EBITDA is 26.73 as of Aug. 07, 2026, which is 96% above its 10-year median of 13.61. GuruFocus rates LTS:0RO5 with a GF Score™ of 70/100 and a GF Value™ of lei1.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 510 Healthcare Providers & Services companies, Med Life ranks worse than 83.92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Med Life's enterprise value is lei8,199 Mil.
Med Life's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was lei307 Mil. Therefore, Med Life's EV-to-EBITDA for today is 26.73.
The historical rank and industry rank for Med Life's EV-to-EBITDA or its related term are showing as below:
LTS:0RO5'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.55 Med: 13.61 Max: 31.06
Current: 26.75
During the past 11 years, the highest EV-to-EBITDA of Med Life was 31.06. The lowest was 7.55. And the median was 13.61.
LTS:0RO5's EV-to-EBITDA is ranked worse than 83.92% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs LTS:0RO5: 26.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-07), Med Life's stock price is lei11.3753.
Med Life's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was lei0.002. Therefore, Med Life's PE Ratio (TTM) for today is 5,687.65.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Med Life's share price for today is lei11.3753.
Med Life's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Med Life's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RO5 vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Med Life's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Med Life's EV-to-EBITDA falls into.
Med Life's current Enterprise Value is lei8,199 Mil.
Med Life's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei307 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life (LTS:0RO5) has a EV-to-EBITDA of 26.73 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Med Life. This is 96% above median its historical median of 13.61. Over the past decade, Med Life's EV-to-EBITDA has ranged from 7.55 to 31.06. According to the industry distribution chart, Med Life ranks #428 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 83.9%.
Is Med Life's EV-to-EBITDA too high?
Med Life's current EV-to-EBITDA of 26.73 is 96% above median its 10-year median of 13.61. Over the past 10 years, this metric has ranged from a low of 7.55 to a high of 31.06. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.92. Med Life's value of 26.73 is 144.8% above this industry median. Based on the distribution chart, Med Life ranks #428 out of 510 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Med Life has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #428 out of 510 companies for EV-to-EBITDA. This places Med Life in the lower half of its industry. The industry median EV-to-EBITDA is 10.92. Med Life's value of 26.73 is 144.8% above this benchmark. Historically, Med Life's own EV-to-EBITDA has ranged from 7.55 to 31.06 over the past decade. While the company's 10-year median is 13.61 vs. the industry median of 10.92, Med Life has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current EV-to-EBITDA of 26.73 is 144.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Med Life. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current EV-to-EBITDA is 26.73, which is 96% above median its own 10-year median of 13.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.41, compared to a current price of lei11.38 — trading 706.8% above its estimated fair value. The current EV-to-EBITDA is 26.73, which is 96% above median its 10-year median of 13.61 and 144.8% above the Healthcare Providers & Services industry median of 10.92. Med Life's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current EV-to-EBITDA is 26.73 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.38 is trading 706.8% above its estimated GF Value™ of lei1.41.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
EV-to-EBITDA: 26.73 (96% above median its 10-year median of 13.61)
GF Value™: lei1.41 vs. price of lei11.38 (706.8% above fair value)
Industry Position: 144.8% above the Healthcare Providers & Services median (#428 of 510)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
70GF Score
Get the complete analysis for LTS:0RO5
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
